Cingulate Inc. has substantially completed manufacturing work to address FDA requests for its ADHD drug CTx-1301 and plans to resubmit the new drug application between December 2026 and January 2027. The FDA previously issued a Complete Response Letter requesting additional manufacturing information but raised no safety or efficacy concerns. The company reported a net loss of $7.7 million for Q3 2026 and has $23.2 million in cash, expecting to fund operations into mid-2027. The resubmission could lead to FDA review within two to six months, advancing Cingulate's goal to bring a next-generation ADHD treatment to market.
Cingulate Inc.'s Q3 2026 financial results and regulatory update provide context for health sector trends. For readers following health stocks, here is Pluang's market snapshot as of Nov 14, 2026 04:11 WIB: out of 150 priced US health-sector stocks, 71 rose and 75 fell. Notable movers include Alnylam Pharmaceuticals at USD 165.74 with a 5.80% increase and Canopy Growth Corp at USD 0.57 down 5.79%.
ArrowMark Financial Corp. announced a monthly cash distribution of $0.15 per share for November 2026, payable on November 30 to shareholders of record as of November 23. This distribution reflects the company's ongoing commitment to provide current i...
Liberty Defense Holdings clarified details of its credit facility and term loan with Parabilis, originally announced in 2024. The company’s subsidiary received a $1.8 million term loan and a $2.5 million revolving credit facility, both secured by sub...
Stardust Power announced a $2.8 million net loss for Q3 2026, an improvement from $4.5 million last year, driven by lower administrative costs and warrant value changes. The company is progressing its lithium refinery project in Muskogee, Oklahoma, d...
byNordic Acquisition Corporation, a special purpose acquisition company, has extended its deadline to complete a business combination by one month, moving it from November 12, 2026, to December 12, 2026. This is the fourth of up to twelve possible on...
Texas Pacific Land Corporation reported a high Return on Invested Capital (ROIC) of 30.81%, significantly surpassing its Weighted Average Cost of Capital (WACC) of 7.73%. This strong performance results in the highest ROIC-to-WACC ratio of 3.98 among...
